ClearNote Health Unveils Avantect Pancreatic Cancer Test Data at DDW 2026
Event summary
- ClearNote Health will present data on its Avantect Pancreatic Cancer Test at Digestive Disease Week (DDW) 2026, showcasing an 82.6% detection sensitivity and 97.5% specificity.
- The test combines 5hmC-based epigenomic profiling with machine learning algorithms for early pancreatic cancer detection.
- ClearNote Health appointed Jeffrey Venstrom, MD, as Chief Medical Officer to lead clinical strategy.
- The Avantect test is being used in the NHS's SAFE-D study and the PRECEDE Consortium for pancreatic cancer surveillance.
The big picture
ClearNote Health's presentation at DDW 2026 underscores the growing emphasis on liquid biopsy technologies for early cancer detection. The company's multi-analyte approach positions it as a key player in the shift toward precision oncology, particularly in high-mortality cancers like pancreatic. Its partnerships with major health systems and consortia signal increasing validation of its diagnostic platform.
What we're watching
- Clinical Validation
- Whether the Avantect test's performance metrics hold up in broader real-world validation studies.
- Regulatory Pathway
- The pace at which ClearNote Health advances regulatory approvals for its multi-cancer detection tests.
- Market Adoption
- How quickly gastroenterologists integrate the Avantect test into surveillance protocols for high-risk patients.
Related topics